Moonlake Immunotherapeutics Earnings

Moonlake Immunotherapeutics’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated NaN% jump in its revenue since last 3-months.

Moonlake Immunotherapeutics’s net profit fell -127.55% since last year same period to $-55.22Mn in the Q2 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated -37.18% fall in its net profits since last 3-months.

Moonlake Immunotherapeutics’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated NaN% jump in its net profit margins since last 3-months.

Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.86 - a -19.6% fall from last quarter’s estimates.

Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current year stand at -0.86.

Moonlake Immunotherapeutics’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Moonlake Immunotherapeutics has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.